Conclusão: Não foi encontrada associação significativa entre o polimorfismo PD1.3 e a susceptibilidade ao LES ou à AR nesta população do sul do Brasil.
Introduction
Autoimmune rheumatic diseases share clinical findings and are caused by multiple factors including a complex genetic basis coupled with non-genetic factors, which contribute in different degrees for each affected individual. 1 Genetic polymorphisms of the human genome have been investigated and new evidence of genetic contribution to rheumatic diseases has been discovered. Among autoimmune diseases, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), have been the main targets of genetic variation studies, once they represent multisystem disorders with a wide spectrum of clinical manifestations. 1, 2 SLE affects mainly women of reproductive age, and its major characteristic is the production of autoantibodies against nuclear antigens, as double stranded DNA (dsDNA), ribonucleoproteins (RNP) and Smith (Sm) antigen; as well as cytoplasmic, and cell-surface antigens. 3 These autoantibodies deposit on several organs causing inflammation and leading to symptoms that could range from subtle to life-threatening. Constitutional manifestations including fever, fatigue and weight loss may occur, as well as joint pain due to arthritis, malar and discoid rashes, photosensitivity, and involvement of the central and peripheral nervous system, kidneys, heart and lungs. 1 Progression of the disease is individual and heterogeneous, so different biomarkers have been sought in order to unveil disease susceptibility and development as well as to guide therapeutic decisions. 4, 5 RA pathogenesis is complex and results in chronic inflammation of joints and, in many patients, systemic complications, such as subcutaneous nodules, pulmonary involvement and early atherosclerosis, that may be challenging regarding treatment. 6 In order to come to better prognosis and outcomes in RA, the development of biomarkers that allow disease sub-categorization are needed. 7 So far, serologic factors such as rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA); and the acute inflammation marker C-reactive protein (CRP), have helped classifying RA clinical phenotypes. [8] [9] [10] [11] Rheumatoid factor is an autoantibody directed against the Fc portion of IgG, and correlates with the severity of the disease 12 ; whereas the ACPA are directed against citrullinated proteins, and can also help to predict a more severe and erosive disease. 13 Although the etiology of SLE and RA are not well established, it is hypothesized that deregulated lymphocyte activation play an important role in the breakdown of immune tolerance, leading to autoreactivity. 2, 14 Involved in this processes, co-stimulatory molecules are critical for the balance between T cell activation and inhibition. 15 Among those, the programmed cell death 1 (PD-1) is shown to be an important molecule involved in profound loss of self-tolerance leading to rapid lethality associated with lymphocyte infiltration in many organs. 16 This protein is expressed on the surface of T, B and myeloid cells, and is a member of the CD28 family that belongs to the immunoglobulin superfamily and acts as an inhibitory molecule on T cells, after interacting with its ligands PDL-1 and PDL-2 (programmed cell death 1 ligand 1 and 2). 17 After initial activation of T cell interactions, PD-1-PD-L may limit autoreactive T cell proliferation and cytokine production, whereas stimulated by antigens the PD-1 dampens T cell receptor (TCR) signaling. The amount of expression of PD-1 and the degree of involvement between this protein and its ligands regulate the threshold of T cell activation and the amount of cytokines produced. 18, 19 PD-1-deficient mice develop spontaneous autoimmune diseases, indicating an essential function of PD-1 in the mechanisms of tolerance. [20] [21] [22] [23] PD-1 is encoded by the PDCD1 gene, located at 2q37.3 locus. Among the SNPs found within this region, the PD1.3G/A (rs11568821) potentially represents a functional polymorphism associated with the transcriptional regulation of PD-1. 24 The PD1.3A allele alters the binding site of RUNX1 (or AML1) transcription factor, located on the intron 4 enhancer region, which could lead to aberrant protein expression, suggesting a mechanism for the self-tolerance breakdown. 25, 26 Association studies correlated the presence of the allele PD1.3A with SLE in Mexican and Scandinavian populations, 25 and with diabetes mellitus 1 and RA in Denmark and Sweden respectively. 26, 27 However, some populations in Asia are non-polymorphic for this genomic region, presenting only the PD1.3G allele, [28] [29] [30] which emphasizes the diversity of allelic frequency among populations, and supports the necessity to study the association of this PDCD1 polymorphism in other localities. In Brazil, three studies have evaluated the frequencies of PD1.3 polymorphism. One in patients with pemphigus foliaceus (also an autoimmune disease), 31 in silica-exposed workers, 32 and in a cohort of patients with Chagas disease, 33 demonstrating the presence of both alleles in this population. Regarding clinical data, we evaluated SLE patient's medical chart records of arthritis, photo-sensibility, Raynaud's phenomenon, and nephritis, which were the recurrent clinical manifestation in this group. For RA patients, we considered rheumatoid factor (RF) positivity (>20 IU/ml), and levels of C-reactive protein (CRP) above the reference value (>5 mg/l) as the laboratorial manifestations to be associated with the alleles. Whole blood samples were obtained from SLE and RA patients and from control subjects. The DNA was extracted using the phenol-chloroform technique. 34 The PD1.3A (PDCD1) allele was detected by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). 35 The PCR product of 180 bp was digested by PstI restriction endonuclease (BioLabs Inc., New England), according to the manufacturer instructions. All experiments were performed with negative and positive internal controls previously genotyped at Laboratório de Genética Molecular Humana -UFPR. The product of digestion was stained with GelRed ® solution and subjected to electrophoresis on a 3% agarose gel. DNA was visualized with a photographed gel documentation system (MiniBISPro DNR). The genotype was classified according to the size of the generated fragments (GG -180 bp; GA -180 bp, 150 bp and 30 bp; AA -150 bp and 30 bp).
Hardy-Weinberg equilibrium (HWE) was tested using the 2 test. Allele and genotype frequencies were estimated by direct counting. Allele and genotype frequencies were compared between patients and controls by Fisher exact test using SPSS (version 20.0; SPSS Inc., Chicago, IL), which was also used to calculate the odds ratio (OR) in order to determine the association of the PD1.3A allele and the studied diseases, as well as its association to poor prognosis factors of SLE and RA patients. A p value of 0.05 was adopted as the limit of significance for all tests.
Results
The allele and genotype frequencies of PD1.3 polymorphisms found among the groups are shown in Table 2 . The genotype distribution in the control group was in HWE ( 2 (1) = 2.24, p = 0.13), but the distributions observed in SLE and RA patients were not ( 2 (1) = 6.60, p = 0.01 for SLE and 2 (1) = 9.02, p < 0.001 for RA). Nevertheless, no association was found regarding the alleles or genotypes and both diseases (p > 0.05) ( Table 2) .
Among SLE patients, 49.5% had arthritis, 40.0% complained of photosensitivity, 15.8% experienced the Raynaud's phenomenon and 30.5% presented renal impairment. Association between these clinical factors and PD1.3 alleles and genotypes were analyzed, but no significant results were found (Table 3) .
Less than half of RA patients (46.15%) presented high level of CRP, and 66.67% had RF positivity. However, those factors were not associated with the presence of PD1.3A allele either in homozygosis or heterozygosis (Table 3) . 
Discussion
For the first time in Brazil, PDCD1 gene was considered a candidate for susceptibility to systemic lupus erythematosus (SLE) and to rheumatoid arthritis (RA). Associations between the SNP PD1.3A and clinical and laboratorial manifestations were tested, finding no statistically significant results. Once genotype frequencies of SLE and RA patients were not in Hardy-Weinberg equilibrium (Table 3) , diverging from the control group, a putative association with these diseases was investigated. The frequency of AA genotype was very low in all groups (0.032 in SLE, 0.046 in RA and 0.016 in controls) as shown by other case-control studies in different populations, where AA frequencies were all below 0.05. 31, 33, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] One Iranian cohort, however, has shown AA genotype frequencies of 0.20 in controls and 0.44 in patients with Colorectal Cancer (CCR), revealing as well, an association between this genotype and CCR (p = 0.0005). 45 In Brazil, the frequency of the AA genotype was also low according to three different cohorts involving patients with Chagas disease (0.03 and 0.01 in controls), 33 pemphigus foliaceus (0.007 and 0.01 in controls), 31 and reaching 0% in a group of silica-exposed workers (0.03 in controls). 32 Interestingly, some populations carry the minor allele, but no homozygous description was found, presenting only GG and AG individuals. Yet, the analyzed genotypes showed no statistically significant OR value when considering the risk of developing SLE or RA in our study. 35, [46] [47] [48] Associations of the PD1.3A allele to disease development have been increasingly investigated, not only in SLE and RA patients, 25, 26, 28, 29, [35] [36] [37] 46, [49] [50] [51] [52] [53] [54] [55] but also in other autoimmune and chronic inflammatory diseases such as Diabetes Mellitus type I (T1D), 27, 38, 42 Graves and Addison disease, 39 Ankylosing spondylitis, 44 and Myasthenia Gravis, 41 as well as in other conditions as CCR, 45 and silica exposed workers (Table 4) . 32 The PD1.3A allele frequency highly differs among populations worldwide, three Chinese studies related to RA and Vogt-Koyanagi-Harada Syndrome found no allele variation in their population, 28, 30, 55 which was also observed in Japan in a similar study. 29 European studies show the presence of the PD1.3 polymorphism, yet association to diseases varies among studies. An association of PD1.3A to SLE was demonstrated by Prokunina et al. 25, 26 in European women and Mexicans, and by Ferreiros-Vidal et al. 51 in SLE patients from Germany, Czech Republic and Hungary. Nevertheless, Ferreiros-Vidal et al. have previously shown a reversal of patterns in a Spanish cohort, with decreased risk of SLE development in PD1.3A carriers. 50 RA patients were also genotyped for PDCD1 rs11568821 polymorphism by few groups, 28, 29, 36, 55 and as mentioned previously, Chinese and Japanese cohorts carried solely the PD1.3G allele. A Swedish study was the only one to present data on RA and rs11568821 polymorphism, but association between the disease and allele or genotypes was not demonstrated. 36 Nonetheless, the same group showed an association of PD1.3A and RA patients negative for RF. In the present study we could not find any association between RF positivity or high levels of CRP and the alleles or genotypes investigated.
SLE patients were also inquired about clinical manifestations as arthritis, photosensitivity, Raynaud's phenomenon, and renal involvement. However, we found no association between PD1.3 alleles or genotypes and these manifestations. Thorburn et al. 53 evaluated the role of four PDCD1 SNPs (PD1.1A, PD1.3A, PD1.5T and PD1.6A) and SLE nephritis, arthritis, antiphospholipid antibody (APA), and double-stranded DNA positivity, finding no association of PD1.3A allele and its associated haplotype and any clinical phenotype. The occurrence of APA in SLE patients was also analyzed by Sanghera et al. 35 unraveling a protection of PD1.3A carriers against APA in both SLE (OR = 0.57; 95% CI: 0.32-1.01) and controls (OR = 0.40; 95% CI: 0.19-0.82). Prokunina et al., 26 Johansson et al., 37 and Nielsen et al. 49 evaluated renal manifestations in SLE patients. The first and second studies showed an association between the PD1.3A allele and renal disorders in patients with SLE from Sweden (OR = 2.6; 95% CI: 1.4-4.8, and OR = 2.62; 95% CI: 1.28-5.35, respectively); and the third one did not find an association of lupus nephropathy and the minor allele of PD1.3. As for RA, neither RF nor CRP was associated to PD1.3A allele presence either in homozygosis or heterozygosis, as opposed to what was found by Prokunina et al. 26 Although studies show the PD1.3 G/A polymorphism associated with RA, SLE and other autoimmune diseases and their clinical manifestations, our study revealed no differences in minor allele carries between RA and SLE patients and controls neither disease manifestations. 
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